Alternative Commercialisation Models Offer Lifeline to Future of Gene Therapies
Nonprofit founder and CEO, Craig Martin, notes that the industry will likely see more alternative gene therapy commercialisation models in the future.
Fondazione Telethon and Orphan Therapeutics Accelerator Sign Memorandum of Understanding to Pioneer Non-Profit Commercial Access Model for Ultra-Rare Disease Gene Therapy in the US
Collaboration Aims to Establish Sustainable Access to a Newly Approved Therapy Targeting a Rare Immunodeficiency, Filling Urgent Gap Left by For-Profit Efforts
Orphan Therapeutics Accelerator Launches Orphan Therapies, a Non-Profit Biotech Dedicated to Commercializing Ultra-Rare Disease Treatments
Orphan Therapeutics Accelerator (OTXL), a non-profit organization focused on advancing shelved ultra-rare disease treatments through clinical trials, today announced the launch of its wholly owned subsidiary, Orphan Therapies (OT) LLC. Orphan Therapies will focus on commercializing and providing sustained, equitable patient access to approved therapies for conditions with very small patient populations.